OptiBiotix files two new cholesterol reducing patents

London stock exchange listed OptiBiotix Health plc, a life sciences business developing compounds to tackle obesity, highcholesterol and diabetes, has announced the filing of two new patents covering its cholesterol reducing product. This increases the number of patents from nine to eleven.

Company said on Tuesday in a press release that it believes that filing these patents adds a further layer of protection to its intellectual property portfolio, creates valuable assets, and increases the number of product opportunities.

Stephen O’Hara, CEO of OptiBiotix, commented:

“We are pleased to announce the filing of these patents which add a further level of protection and value to our cholesterol reducing product. We believe these  patents will further enhance the value proposition and negotiating position with commercial partners and make a significant contribution to building a successful and sustainable business for shareholders.”

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s